NEW YORK (TheStreet) -- Molycorp (MCP - Get Report) was rising 14.4% to $2.31 after-hours Wednesday after announcing a $400 million financing arrangement, and despite missing estimates for the second quarter.
The company announced that it secured a $400 million financing arrangement managed by Oaktree Capital Management. Oaktreee will provide Molycorp with up to $400 million in secure financing through credit facilities and the sale and leaseback of some equipment at Molycorp's Mountain Pass facility.
News of the agreement comes as Molycorp reported a loss of -29 cents for the second quarter, below the Capital IQ Consensus Estimate of a loss of -28 cents a share. Revenue fell -14.5% from the year-ago quarter to $116.9 million. Analysts expected Molycorp to report revenue of $130.97 million for the quarter.
Must read: Warren Buffett's 25 Favorite StocksSTOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more. TheStreet Ratings team rates MOLYCORP INC as a Sell with a ratings score of D. TheStreet Ratings Team has this to say about their recommendation: "We rate MOLYCORP INC (MCP) a SELL. This is driven by several weaknesses, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. The company's weaknesses can be seen in multiple areas, such as its unimpressive growth in net income, weak operating cash flow, generally disappointing historical performance in the stock itself and generally high debt management risk." Highlights from the analysis by TheStreet Ratings Team goes as follows:
- You can view the full analysis from the report here: MCP Ratings Report
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts